Therefore, EGFR and ERBB2 differentially impact ERBB signaling during pancreatic cancer tumorigenesis, highlighting the need to consider patient’s specific characteristics of ERBB signaling to optimize therapeutic treatment. The gene discussed is ERBB2; the disease is familial pancreatic carcinoma.